Abstract | BACKGROUND: METHODS: As a note of caution, we describe a 57-year-old woman who received therapy with anti- TNF- alpha antibodies for RA refractory to methotrexate. After almost 2 years of treatment, she developed a severe cytomegalovirus (CMV) retinitis of the right eye. RESULTS: Laboratory assays revealed an immune status with nearly total loss of the cellular immune response and partial reduction of the humoral immune response. Intravenous treatment with ganciclovir, followed by oral administration of valganciclovir, resulted in an ophthalmological remission. Cessation of immunosuppressive therapy led to partial immunological reconstitution in the patient. Six months after discontinuation of immunosuppressive therapy, CMV retinitis of the left eye occurred but was treated successfully with a second course of oral valganciclovir. CONCLUSION:
|
Authors | Georg Haerter, Burkhard J Manfras, Yvonne de Jong-Hesse, Heike Wilts, Thomas Mertens, Peter Kern, Michael Schmitt |
Journal | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
(Clin Infect Dis)
Vol. 39
Issue 9
Pg. e88-94
(Nov 01 2004)
ISSN: 1537-6591 [Electronic] United States |
PMID | 15494900
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Antibodies, Monoclonal
- Antiviral Agents
- Tumor Necrosis Factor-alpha
- Infliximab
- Valganciclovir
- Ganciclovir
|
Topics |
- Antibodies, Monoclonal
(adverse effects, immunology)
- Antiviral Agents
(therapeutic use)
- Arthritis, Rheumatoid
(complications, drug therapy, immunology)
- Cytomegalovirus Retinitis
(chemically induced, complications, drug therapy, immunology)
- Female
- Ganciclovir
(analogs & derivatives, therapeutic use)
- Humans
- Infliximab
- Middle Aged
- Tumor Necrosis Factor-alpha
(immunology)
- Valganciclovir
|